DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,034 filers reported holding DANAHER CORPORATION in Q1 2023. The put-call ratio across all filers is 0.99 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $241,898 | -7.1% | 975 | -10.1% | 0.10% | -3.8% |
| Q2 2023 | $260,400 | -46.2% | 1,085 | -43.5% | 0.10% | -46.1% |
| Q1 2023 | $484,456 | -3.5% | 1,922 | +1.6% | 0.19% | -8.1% |
| Q4 2022 | $502,175 | +8.0% | 1,892 | +3.2% | 0.21% | +6.1% |
| Q3 2022 | $465,000 | 0.0% | 1,834 | 0.0% | 0.20% | 0.0% |
| Q2 2022 | $465,000 | -12.8% | 1,834 | +0.9% | 0.20% | -0.5% |
| Q1 2022 | $533,000 | 0.0% | 1,818 | +12.2% | 0.20% | 0.0% |
| Q4 2021 | $533,000 | +7.7% | 1,620 | -0.4% | 0.20% | +7.6% |
| Q3 2021 | $495,000 | +6.0% | 1,627 | -6.5% | 0.18% | +8.8% |
| Q2 2021 | $467,000 | +11.7% | 1,740 | -6.4% | 0.17% | 0.0% |
| Q1 2021 | $418,000 | +1.0% | 1,859 | -0.3% | 0.17% | -6.1% |
| Q4 2020 | $414,000 | +3.0% | 1,865 | -0.1% | 0.18% | -12.1% |
| Q3 2020 | $402,000 | +18.2% | 1,866 | -2.9% | 0.21% | +6.7% |
| Q2 2020 | $340,000 | +39.9% | 1,922 | +9.6% | 0.19% | +14.2% |
| Q1 2020 | $243,000 | -0.4% | 1,753 | +10.4% | 0.17% | +7.0% |
| Q4 2019 | $244,000 | +9.4% | 1,588 | +2.7% | 0.16% | -1.9% |
| Q3 2019 | $223,000 | +4.2% | 1,546 | -5.3% | 0.16% | +18.4% |
| Q1 2019 | $214,000 | +33.8% | 1,633 | +5.1% | 0.14% | +11.5% |
| Q4 2018 | $160,000 | – | 1,554 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 241,441 | $70,822,000 | 14.94% |
| Defender Capital, LLC. | 143,752 | $42,381,000 | 14.74% |
| Third Point | 2,490,000 | $730,392,000 | 9.51% |
| Riverstone Advisors, LLC | 63,015 | $18,484,000 | 9.49% |
| 11 Capital Partners LP | 96,063 | $28,178,000 | 8.99% |
| Eos Focused Equity Management, L.P. | 34,026 | $9,981,000 | 8.54% |
| CORTLAND ASSOCIATES INC/MO | 187,609 | $55,031,000 | 7.01% |
| Mirova US LLC | 1,242,440 | $364,444,000 | 7.00% |
| Front Street Capital Management, Inc. | 118,397 | $34,729,000 | 6.47% |
| Alphinity Investment Management Pty Ltd | 909,181 | $266,690,000 | 6.21% |